On The Exosome/Extracellular Vesicle Frontier, Choose Your Own Adventure

Crystal Cruz, Bioprocessing Consultant for Roosterbio, and David Haylock, Ph.D., CEO, VivaZome Therapeutics held a lively conversation following the "Manufacturing Advances Unlock the Therapeutic Potential of MSC-Derived Exosomes" webinar. In this article you will gain insights from this webinar including Cruz's explanation of how early pivotal bioprocess decisions made in parallel with preclinical development help the investigator pass through some known challenges with steady momentum and resiliency.

In-depth discussions cover how critically important scalability is for future clinical products made from extracellular vesicles, how quality of peer-reviewed extracellular vesicle / exosome science can improve, and how VivaZome Therapeutics are leading the way into a new therapeutic ecosystem.